Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004578 · ClinicalTrials.gov registry record · Phase 1
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT00004578 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 100 participants.
The verdict
NCT00004578, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
Interventions
- DRUG Lamivudine
- DRUG Stavudine
- DRUG Lopinavir/Ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 1997-11 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004578
The ClinicalTrials.gov registry entry for NCT00004578 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lamivudine is the first listed.
NCT00004578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004578 about?
NCT00004578 is a clinical study titled "ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects". To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
What is the current status of trial NCT00004578?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 1997-11. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00004578?
The interventions under investigation include: Lamivudine (DRUG), Stavudine (DRUG), Lopinavir/Ritonavir (DRUG).
Who is sponsoring clinical trial NCT00004578?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.